<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - 獲取免費報告) 的股價在週一的午盤交易中創下 52 周新低。該公司的股價最低跌至 1.61 美元，最後交易價格為 1.79 美元，成交量為 157953676 股。該股票此前收盤價為 5.03 美元。</p>
<p>獲取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>分析師仍看好前三家高動量公司</li>
</ul>
<p>多家股票研究分析師最近對該公司發佈了報告。HC Wainwright 在週一的研究報告中重申了 “買入” 評級，並對 Compass Therapeutics 的股票設定了 24.00 美元的目標價。Wall Street Zen 在週六的研究報告中將 Compass Therapeutics 的評級從 “持有” 下調至 “賣出”。Guggenheim 在 3 月 24 日的研究報告中重申了 “買入” 評級，並對 Compass Therapeutics 的股票設定了 12.00 美元的目標價。William Blair 在 3 月 5 日的研究報告中重申了對 Compass Therapeutics 股票的 “跑贏大盤” 評級。最後，Craig Hallum 在 2 月 13 日的報告中開始覆蓋 Compass Therapeutics。他們設定了 “買入” 評級和 15.00 美元的目標價。一位投資分析師對該股票給予了強烈買入評級，十二位分析師給予了買入評級，一位分析師對該公司給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 14.20 美元。</p>
<p><strong>閲讀我們關於 CMPX 的最新報告</strong></p>
<h2>Compass Therapeutics 股票下跌 64.4%</h2>
<p>該公司的市值為 3.2236 億美元，市盈率為-4.16，貝塔值為 1.49。該股票的 50 日移動平均線為 5.46 美元，200 日移動平均線為 5.28 美元。</p>
<p>Compass Therapeutics (NASDAQ:CMPX - 獲取免費報告) 最近在 3 月 5 日發佈了其財報。該公司報告每股收益（EPS）為-0.09 美元，超出分析師的共識預期（-0.10 美元）0.01 美元。股票分析師預測 Compass Therapeutics, Inc. 在當前財政年度將發佈-0.41 的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>對沖基金和其他機構投資者最近買賣了該公司的股票。Flagship Harbor Advisors LLC 在第四季度購買了 Compass Therapeutics 的新股份，價值約 32,000 美元。Russell Investments Group Ltd. 在第三季度將其在 Compass Therapeutics 的持股增加了 3933.7%。Russell Investments Group Ltd. 現在擁有該公司 7,785 股股票，價值 27,000 美元，此前在此期間又購買了 7,592 股。Apollon Wealth Management LLC 在第三季度購買了 Compass Therapeutics 的新頭寸，價值 35,000 美元。Xponance LLC 在第四季度購買了 Compass Therapeutics 的新頭寸，價值 55,000 美元。最後，CIBC Bancorp USA Inc. 在第三季度購買了價值約 37,000 美元的 Compass Therapeutics 新股份。機構投資者持有該公司 68.43% 的股票。</p>
<h2>Compass Therapeutics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Compass Therapeutics, Inc 是一家臨牀階段的生物技術公司，致力於新型免疫腫瘤療法的發現和開發。公司總部位於馬薩諸塞州劍橋，專注於工程化單克隆抗體候選藥物，旨在增強 T 細胞介導的抗腫瘤反應。Compass 利用專有抗體平台識別和優化調節免疫檢查點通路和腫瘤微環境的生物製劑。</p>
<p>該公司的主要項目包括 CTX-471，一種雙特異性抗體，靶向 PD-1 和 PD-L1 檢查點，以及 DSP107，一種 CD47-SIRPα 通路調節劑，旨在破壞癌細胞上的 “別吃我” 信號。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Compass Therapeutics</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Compass Therapeutics 嗎？</h2>
<p>在你考慮 Compass Therapeutics 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Compass Therapeutics 並不在名單上。</p>
<p>雖然 Compass Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CMPX

<p>Compass Therapeutics（納斯達克代碼：CMPX）股價創下 52 周新低，報 1.61 美元，收盤價為 1.79 美元，交易量顯著。分析師的評級意見不一：HC Wainwright 維持 “買入” 評級，目標價為 24 美元，而 Wall Street Zen 則下調至 “賣出”。該股票市值為 3.2236 億美元，市盈率為-4.16。機構投資者持有 68.43% 的股份。該公司專注於免疫腫瘤治療，報告的每股收益為（0.09 美元），略高於預期。分析師預測評級為適度買入，平均目標價為 14.20 美元</p>

<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $1.61 and last traded at $1.79, with a volume of 157953676 shares trading hands. The stock had previously closed at $5.03.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc. (NASDAQ:CMPX - 獲取免費報告) 的股價在週一的午盤交易中創下 52 周新低。該公司的股價最低跌至 1.61 美元，最後交易價格為 1.79 美元，成交量為 157953676 股。該股票此前收盤價為 5.03 美元。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師仍看好前三家高動量公司</li>
</ul>
</div><p>A number of equities research analysts recently issued reports on the company. HC Wainwright reissued a &#34;buy&#34; rating and issued a $24.00 target price on shares of Compass Therapeutics in a research report on Monday. Wall Street Zen downgraded Compass Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday. Guggenheim restated a &#34;buy&#34; rating and issued a $12.00 price target on shares of Compass Therapeutics in a research note on Tuesday, March 24th. William Blair reiterated an &#34;outperform&#34; rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. Finally, Craig Hallum assumed coverage on Compass Therapeutics in a report on Friday, February 13th. They set a &#34;buy&#34; rating and a $15.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $14.20.</p>
<div class="lb-trans"><p>多家股票研究分析師最近對該公司發佈了報告。HC Wainwright 在週一的研究報告中重申了 “買入” 評級，並對 Compass Therapeutics 的股票設定了 24.00 美元的目標價。Wall Street Zen 在週六的研究報告中將 Compass Therapeutics 的評級從 “持有” 下調至 “賣出”。Guggenheim 在 3 月 24 日的研究報告中重申了 “買入” 評級，並對 Compass Therapeutics 的股票設定了 12.00 美元的目標價。William Blair 在 3 月 5 日的研究報告中重申了對 Compass Therapeutics 股票的 “跑贏大盤” 評級。最後，Craig Hallum 在 2 月 13 日的報告中開始覆蓋 Compass Therapeutics。他們設定了 “買入” 評級和 15.00 美元的目標價。一位投資分析師對該股票給予了強烈買入評級，十二位分析師給予了買入評級，一位分析師對該公司給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 14.20 美元。</p>
</div><p><strong>Read Our Latest Report on CMPX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CMPX 的最新報告</strong></p>
</div><h2>Compass Therapeutics Stock Down 64.4%</h2>
<div class="lb-trans"><h2>Compass Therapeutics 股票下跌 64.4%</h2>
</div><p>The company has a market capitalization of $322.36 million, a PE ratio of -4.16 and a beta of 1.49. The stock has a 50-day moving average of $5.46 and a 200 day moving average of $5.28.</p>
<div class="lb-trans"><p>該公司的市值為 3.2236 億美元，市盈率為-4.16，貝塔值為 1.49。該股票的 50 日移動平均線為 5.46 美元，200 日移動平均線為 5.28 美元。</p>
</div><p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Equities analysts forecast that Compass Therapeutics, Inc. will post -0.41 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Compass Therapeutics (NASDAQ:CMPX - 獲取免費報告) 最近在 3 月 5 日發佈了其財報。該公司報告每股收益（EPS）為-0.09 美元，超出分析師的共識預期（-0.10 美元）0.01 美元。股票分析師預測 Compass Therapeutics, Inc. 在當前財政年度將發佈-0.41 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. Flagship Harbor Advisors LLC purchased a new stake in shares of Compass Therapeutics in the 4th quarter worth approximately $32,000. Russell Investments Group Ltd. raised its holdings in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock worth $27,000 after purchasing an additional 7,592 shares during the period. Apollon Wealth Management LLC bought a new position in Compass Therapeutics in the 3rd quarter worth $35,000. Xponance LLC bought a new position in Compass Therapeutics in the 4th quarter worth $55,000. Finally, CIBC Bancorp USA Inc. bought a new stake in Compass Therapeutics during the third quarter valued at about $37,000. Institutional investors own 68.43% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近買賣了該公司的股票。Flagship Harbor Advisors LLC 在第四季度購買了 Compass Therapeutics 的新股份，價值約 32,000 美元。Russell Investments Group Ltd. 在第三季度將其在 Compass Therapeutics 的持股增加了 3933.7%。Russell Investments Group Ltd. 現在擁有該公司 7,785 股股票，價值 27,000 美元，此前在此期間又購買了 7,592 股。Apollon Wealth Management LLC 在第三季度購買了 Compass Therapeutics 的新頭寸，價值 35,000 美元。Xponance LLC 在第四季度購買了 Compass Therapeutics 的新頭寸，價值 55,000 美元。最後，CIBC Bancorp USA Inc. 在第三季度購買了價值約 37,000 美元的 Compass Therapeutics 新股份。機構投資者持有該公司 68.43% 的股票。</p>
</div><h2>Compass Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Compass Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc 是一家臨牀階段的生物技術公司，致力於新型免疫腫瘤療法的發現和開發。公司總部位於馬薩諸塞州劍橋，專注於工程化單克隆抗體候選藥物，旨在增強 T 細胞介導的抗腫瘤反應。Compass 利用專有抗體平台識別和優化調節免疫檢查點通路和腫瘤微環境的生物製劑。</p>
</div><p>The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.</p>
<div class="lb-trans"><p>該公司的主要項目包括 CTX-471，一種雙特異性抗體，靶向 PD-1 和 PD-L1 檢查點，以及 DSP107，一種 CD47-SIRPα 通路調節劑，旨在破壞癌細胞上的 “別吃我” 信號。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Compass Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Compass Therapeutics 嗎？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Compass Therapeutics 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Compass Therapeutics 並不在名單上。</p>
</div><p>While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Compass Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Compass Therapeutics（納斯達克股票代碼：CMPX）創下 12 個月新低 - 接下來會如何發展？